Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.

Butanvac (Coronavirus Vaccine) - Oswaldo Cruz Foundation, Butantan Institute

Patria (Recombinant NDV Vectored Vaccine for SARS-CoV-2) - National Autonomous University of Mexico, Avimex, Mexican Social Security Institute

http://www.ncbi.nlm.nih.gov/pubmed/37164959

May 11, 2023